Compare LPA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | ACRV |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 74.5M |
| IPO Year | N/A | 2022 |
| Metric | LPA | ACRV |
|---|---|---|
| Price | $2.60 | $2.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 29.3K | ★ 431.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $47,536,343.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.20 |
| P/E Ratio | $12.44 | ★ N/A |
| Revenue Growth | ★ 7.28 | N/A |
| 52 Week Low | $2.55 | $1.05 |
| 52 Week High | $11.16 | $8.00 |
| Indicator | LPA | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 55.77 |
| Support Level | $2.65 | $2.12 |
| Resistance Level | $2.94 | $2.59 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 2.38 | 59.17 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.